NCT02566733View on ClinicalTrials.gov

Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Anesthetics, IntravenousPharmacologyAnestheticsCardiopulmonary Bypass
Interventions
DRUG

Remiva

Target controlled infusion of remifentanil (generic drug, Remiva™)

DRUG

Ultiva

Target controlled infusion of remifentanil (brand-named drug, Ultiva™)

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02566733 - Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter